RxDoctor Payments Data

Gautam Verma, MD

Clinical Cardiac Electrophysiology · Flemington, NJNPI 1780942383

Payments from drug & device makers

$11,037in general payments, 2019–2025

Across 175 payments — averaging $63.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Altathera Pharmaceuticals LLC$2K
  • Medtronic$1K
  • Abbott$1K
  • Novartis$358
  • E.r. Squibb & Sons, L.L.C.$312
  • plus $2K from 32 others

What the payments were for

  • Consulting fees$1,87517%
  • Travel & lodging$2,65224%
  • Food & beverage$6,42358%
  • Entertainment$871%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,037 in reported general payments places this provider in the 30th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

See all clinical cardiac electrophysiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$580,886
Medicare patients
1,618
Services billed
6,453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban172$216,495
XareltoRivaroxaban26$30,887
EntrestoSacubitril/Valsartan13$26,224
FarxigaDapagliflozin Propanediol11$17,670
Metoprolol Succinate215$3,315
Digoxin26$3,151
Diltiazem 24hr Er (Cd)Diltiazem Hcl44$1,433
Amiodarone Hcl25$1,317
Matzim LaDiltiazem Hcl13$829
Atorvastatin Calcium77$724
Rosuvastatin Calcium28$595
ClopidogrelClopidogrel Bisulfate22$542
Carvedilol48$500
Warfarin Sodium33$376
Losartan Potassium28$372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$45$216,495172 claims
Johnson & JohnsonXarelto$149$30,88726 claims
NovartisEntresto$358$26,22413 claims
AstraZenecaFarxiga$116$17,67011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

Other clinical cardiac electrophysiology in Flemington

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →